FDA Approves Mannkind’s At-Home Treatment Option for Heart Failure or Kidney Disease
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Mannkind…
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Choosing between established healthcare giants often comes down to balancing income needs against growth potential. Both Bristol Myers…
Cingulate Receives Complete Response Letter from FDA for CTx-1301
Cingulate Inc. No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on CMC-Related RequestsCompany Plans Prompt…
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
Praxis Precision Medicines, Inc. FDA assigned PDUFA target action date of September 27, 2026 BOSTON, March 30, 2026…
Avicanna Announces Sponsorship of University of Calgary THC Dose Finding Clinical Trial
Avicanna Inc. New randomized controlled trial to evaluate dose-dependent effects of oral THC on anxiety and stress using…
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®
BioXcel Therapeutics Company remains focused on potential approval and launch of IGALMI® for the acute treatment of agitation…
Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)
Milestone Pharmaceuticals received U.S. Food and Drug Administration approval of CARDAMYST for the conversion of acute symptomatic episodes…